Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (1064)	3/3/2000 12:54:00 PM
From: scott_jiminez	Read Replies (2) \| Respond to of 4474

Mike - I realize you had one horrendous takedown with a stop/sell on Ariad in the fall. Perhaps yours is the preeminent lesson AGAINST the common wisdom of using stops to 'protect' oneself. Nevertheless, the words flying around your posts do show some bitterness...since the appellation you give me (cheerleader) and the descriptions you apply to Berger's behavior, the CNBC interview, etc, are certainly NOT restricted to Ariad alone. Maybe you're familiar with SI participants who 'adore' other biotechs (such as glia or rgen or incy). Certainly 'lame' could be ascribed to the behavior of some of those choices...and I needn't mention the sustained and deafening 'cheerleading' that has permeated SI for those companies. If I am a 'remarkable cheerleader' for Ariad, then the defenders of countless other biotechs on SI must be classified 'hardcore promoters'. Could you imagine the noise around this place if Gliatech or Regeneron had gone up ~5000% over the past 6 months as Ariad has? But, as it is now, a text search for Ariad reveals not a peep on the biotech threads! Now THAT'S remarkable! So Ariad is slowly being recognized as a major pharmaceutical and the mavens here act as if it doesn't exist. A case could be made that - if these supposed biotech 'experts' represent in their attitude a large segment of the institutional biotech investors - then there remains a substantial pool of investment awaiting Aria. If this is cheerleading, so be it...but it pales compared to what I read on most other biotech threads here. (and BTW, it's an undeniable fact that biotech = lame earnings. To highlight Ariad in that respect was kinda lame in and of itself. Sheeeesh!)